Commission Publications Highlight Urgency Of Rethinking Investment And Procurement Reform

Medicines For Europe Has Called For Clearer Legal Guidance On Generic And Biosimilar Policies

Medicines for Europe has responded to two recent publications from the European Commission, calling for policy reforms to support the role of generic and biosimilar medicines.

Question mark of yellow stars against blue background
Medicines for Europe has urged the EU to rethink investment and reform procurement in favor of off-patent drugs • Source: Shutterstock

Two documents recently published by the European Commission both highlight the role off-patent drugs could have in improving healthcare access in the EU, said industry body Medicines for Europe.

The 2022 Health at a Glance Report examined the key challenges involved in developing a stronger, more resilient healthcare system following the acute phase of the COVID-19 pandemic

More from Generics

More from Products